{"id":"ac220","safety":{"commonSideEffects":[{"rate":"30%","effect":"Fatigue"},{"rate":"25%","effect":"Nausea"},{"rate":"20%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL576982","moleculeType":"Small molecule","molecularWeight":"560.68"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"AC220 is a potent inhibitor of FMS-like tyrosine kinase 3 (FLT3), a receptor tyrosine kinase involved in the development and progression of acute myeloid leukemia (AML).","oneSentence":"Tyrosine kinase inhibitor","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:18:31.666Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute myeloid leukemia"}]},"trialDetails":[{"nctId":"NCT03661307","phase":"PHASE1, PHASE2","title":"Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-10-31","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia","enrollment":73},{"nctId":"NCT04128748","phase":"PHASE1, PHASE2","title":"Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-05-27","conditions":"Acute Myeloid Leukemia, Blasts More Than 10 Percent of Bone Marrow Nucleated Cells, High Risk Myelodysplastic Syndrome","enrollment":52},{"nctId":"NCT04047641","phase":"PHASE1, PHASE2","title":"Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-10-22","conditions":"Acute Myeloid Leukemia, Blasts 20 Percent or More of Bone Marrow Nucleated Cells, High Risk Myelodysplastic Syndrome","enrollment":80},{"nctId":"NCT04493138","phase":"PHASE1, PHASE2","title":"Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-07-21","conditions":"Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm","enrollment":58},{"nctId":"NCT06262438","phase":"PHASE2","title":"CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients","status":"RECRUITING","sponsor":"Princess Maxima Center for Pediatric Oncology","startDate":"2024-02-06","conditions":"Acute Myeloid Leukemia in Children","enrollment":60},{"nctId":"NCT01892371","phase":"PHASE1, PHASE2","title":"Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-11-12","conditions":"FLT3 Gene Mutation Negative, FLT3 Internal Tandem Duplication Positive, Recurrent Acute Myeloid Leukemia","enrollment":73},{"nctId":"NCT03735875","phase":"PHASE1, PHASE2","title":"Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-01-25","conditions":"Acute Myeloid Leukemia With FLT3/ITD Mutation, Recurrent Acute Myeloid Leukemia, Refractory Acute Leukemia","enrollment":8},{"nctId":"NCT02668653","phase":"PHASE3","title":"Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2016-09-01","conditions":"Acute Myeloid Leukemia, Leukemia","enrollment":539},{"nctId":"NCT05849701","phase":"NA","title":"Shock Wave Versus Vacuum Assisted Closure on Chronic Diabetic Foot Ulcer","status":"COMPLETED","sponsor":"Cairo University","startDate":"2022-03-10","conditions":"Chronic Diabetic Foot Ulcer","enrollment":30},{"nctId":"NCT03723681","phase":"PHASE1","title":"Study of Quizartinib in Combination With Standard Therapies in Chinese Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2018-11-05","conditions":"Acute Myeloid Leukemia (AML)","enrollment":7},{"nctId":"NCT03552029","phase":"PHASE1","title":"Milademetan Plus Quizartinib Combination Study in FLT3-ITD Mutant Acute Myeloid Leukemia (AML)","status":"TERMINATED","sponsor":"Daiichi Sankyo","startDate":"2018-12-12","conditions":"Acute Myeloid Leukemia","enrollment":10},{"nctId":"NCT01411267","phase":"PHASE1","title":"AC220 for Children With Relapsed/Refractory ALL or AML","status":"COMPLETED","sponsor":"Therapeutic Advances in Childhood Leukemia Consortium","startDate":"2011-09-01","conditions":"Lymphoblastic Leukemia, Acute, Childhood, Myelogenous Leukemia, Acute, Childhood","enrollment":24},{"nctId":"NCT02039726","phase":"PHASE3","title":"(QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2014-05","conditions":"AML","enrollment":367},{"nctId":"NCT04734600","phase":"NA","title":"EFFECT OF AEROBIC TRAINING VERSUS MYOFACIAL RELEASE ON CLAUDICATION AMONG PREPHERAIL ARTERAIL INSUFFIECENCY PATIENTS","status":"UNKNOWN","sponsor":"ola mohamed elsayed mostafa elgohary","startDate":"2021-02-01","conditions":"Peripheral Arterial Disease","enrollment":40},{"nctId":"NCT03135054","phase":"PHASE2","title":"Combination of Quizartinib and Omacetaxine Mepesuccinate for AML Carrying FLT3-ITD","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2017-10-01","conditions":"AML, FLT3-ITD Mutation","enrollment":40},{"nctId":"NCT00462761","phase":"PHASE1","title":"A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2007-01","conditions":"Acute Myeloid Leukemia, Leukemia, Myelodysplastic Syndrome","enrollment":76},{"nctId":"NCT02984995","phase":"PHASE2","title":"Phase 2 Study of Quizartinib in Participants With Acute Myeloid Leukemia (AML) FLT3 Internal Tandem Duplication (FLT3/ITD) Mutation","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2016-12-08","conditions":"Leukemia, Myeloid, Acute","enrollment":37},{"nctId":"NCT02272478","phase":"PHASE2, PHASE3","title":"Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy Combinations","status":"UNKNOWN","sponsor":"Cardiff University","startDate":"2014-10-30","conditions":"Acute Myeloid Leukaemia, Myelodysplastic Syndrome","enrollment":1600},{"nctId":"NCT01565668","phase":"PHASE2","title":"Open Label Study to Evaluate Safety and Efficacy of 2 Doses of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2012-04","conditions":"Leukemia, Myeloid, Acute","enrollment":76},{"nctId":"NCT00989261","phase":"PHASE2","title":"Efficacy Study for AC220 to Treat Acute Myeloid Leukemia (AML)","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2009-11","conditions":"Acute Myeloid Leukemia","enrollment":333},{"nctId":"NCT01049893","phase":"PHASE1","title":"Dose Finding, Safety and Tolerability Study for AC220 to Treat Advanced Solid Tumors","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2010-01","conditions":"Solid Tumors","enrollment":45},{"nctId":"NCT01390337","phase":"PHASE1","title":"A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML)","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2011-10","conditions":"Leukemia, Myeloid, Acute","enrollment":19},{"nctId":"NCT01468467","phase":"PHASE1","title":"A Study of AC220 Given After Transplant in Subjects With Acute Myeloid Leukemia (AML)","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2012-04","conditions":"Leukemia, Myeloid, Acute","enrollment":13},{"nctId":"NCT02675478","phase":"PHASE1","title":"Phase 1 Study of Quizartinib","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2016-02","conditions":"Relapsed AML, Refractory AML","enrollment":17},{"nctId":"NCT01576185","phase":"","title":"Developing and Treating a Mouse Model of Acute Myeloid Leukemia Using Tissue Samples From Younger Patients With Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2012-05","conditions":"Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies","enrollment":10},{"nctId":"NCT01236144","phase":"PHASE1, PHASE2","title":"A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220,CXCR4 Inhibitor Plerixafor or HSP90 Inhibitor Ganetespib With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome.","status":"COMPLETED","sponsor":"Cardiff University","startDate":"2011-04","conditions":"Acute Myeloid Leukaemia, High Risk Myelodysplastic Syndrome","enrollment":113}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":102,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Quizartinib","ASP2689","quizartinib"],"phase":"phase_2","status":"active","brandName":"AC220","genericName":"AC220","companyName":"Therapeutic Advances in Childhood Leukemia Consortium","companyId":"therapeutic-advances-in-childhood-leukemia-consortium","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tyrosine kinase inhibitor Used for Acute myeloid leukemia.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}